Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
GAITHERSBURG, Md., May 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017.
Conference call details are as follows:
| Date: | Monday, May 8, 2017 | ||
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | ||
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 8, 2017, until 7:30 p.m. ET, May 15, 2017 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
